Equity strategists note that despite short-term consolidation, fundamentals remain robust with double-digit revenue growth forecasts through FY2025 in the obesity drug segment. Stocks of the pharmaceutical company Tilray soar after President Trump posts a video. The share price of Novo Nordisk, the maker of the weight-loss drug Ozempic, has plummeted. Investor sentiment received a boost after new research showed substantial weight-loss benefits among Type 2 diabetes patients, bolstering long-term sales expectations.
